Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT06412744
Other study ID # NL70677.068.19
Secondary ID NL8297
Status Terminated
Phase
First received
Last updated
Start date October 6, 2020
Est. completion date May 1, 2024

Study information

Verified date May 2024
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Study to determine iodine status in dutch pregnant women


Description:

Rationale: Adequate dietary iodine intake is essential to thyroid hormone synthesis, which is key for normal growth, development and metabolism. During pregnancy, maternal iodine needs are increased (recommended intake: 175 µg/day) and iodine deficiency during pregnancy affects brain and cognitive development of the foetus and might lead to pregnancy complications. Despite the use of iodized salt, it has been shown that iodine intake in the Netherlands is declining. Importantly, a recent small study in Groningen indicated a high prevalence of iodine deficiency during pregnancy (83% of participants) which was not completely restored by 16-week iodine supplementation (150 ug/d). Also in other Western European countries (i.e. Belgium, U.K., North Ireland, Sweden, Denmark and Austria) low median urinary concentrations of iodine (73-124 ug/L) have been observed in pregnant women. Notably, most studies collected spot-urine samples and a 24h urine collection, the golden standard for determination of iodine status, is lacking. Therefore, here it is proposed to measure 24h median urinary iodine concentration corrected for urinary volume and creatinin levels in pregnant women, and compare these values with Thyroglobulin (Tg)-concentrations in serum as measure for iodine intake over a longer period of time. It is hypothesised that the iodine status of pregnant women in The Netherlands is lower than the national recommended intake for this target group.


Recruitment information / eligibility

Status Terminated
Enrollment 43
Est. completion date May 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Female - 18-45y old - in first 16 weeks of pregnancy - pregnant of singleton Exclusion Criteria: - Thyroid-disease or any other metabolic disease - kidney disease - twin-pregnancy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Maastricht UMC+ Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center National Institute for Public Health and the Environment (RIVM)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median urinary iodine excretion (µg/d) Median urinary iodine excretion (µg/d) At baseline measurement
Secondary Thyroglobulin and thyroglobulin antibody concentrations in blood serum Thyroglobulin and thyroglobulin antibody concentrations in blood serum At baseline measurement
Secondary Creatinin concentration in urine Creatinin concentration in urine At baseline measurement
Secondary Urinary volume Urinary volume At baseline measurement
Secondary Smoking status (smoking is interfering with iodine metabolism) Smoking status (smoking is interfering with iodine metabolism) Yes/no At baseline measurement
Secondary Vegan/Vegetarian y/n (soy is competitive for iodine on thyroid) Vegan/Vegetarian y/n (soy is competitive for iodine on thyroid) At baseline measurement
Secondary Nutritional intake specifically related to iodine intake (questionnaire) Nutritional intake specifically related to iodine intake (questionnaire) Iodine specific ffq At baseline measurement
Secondary Intake other relevant micronutrients for pregnant Intake other relevant micronutrients for pregnant At baseline measurement
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1